A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the treatment and safety of a 10-day course of
rifaximin (Xifaxan) as compared to vancomycin for treatment of Clostridium
difficile-associated diarrhea (CDAD).
Phase:
Phase 3
Details
Lead Sponsor:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.